Posters

Single US surgeon’s early experience with iStent inject® trabecular micro-bypass stents implanted in conjunction with cataract surgery

Poster Details

First Author: P.Singh USA

Co Author(s):    M. Gallardo                    

Abstract Details

Purpose:

This case series aims to evaluate the outcomes of a single US surgeon’s experience with iStent inject® (2nd generation trabecular micro-bypass stents) in combination with cataract surgery to treat a population comprised of largely Hispanic patients with OAG.

Setting:

Private-practice ophthalmology center in El Paso, Texas.

Methods:

This is a case series analysis of consecutive eyes implanted with iStent inject in conjunction with cataract surgery by a single US glaucoma surgeon. Preoperative and postoperative measures include intraocular pressure (IOP), medication usage, visual field mean deviation (VF MD), visual acuity, slit lamp and funduscopy exam findings. Intraoperative and postoperative complications and adverse events as well as secondary glaucoma surgeries will be recorded. Additional cases will be added to the analysis as well as longer-term follow-up with the intent of reporting a more robust dataset at the time of the presentation later this year.

Results:

With the recent introduction of iStent inject in the US, the surgeon has successfully implanted the stents in 47 eyes (41.2% Caucasian, 58.8% Hispanic). Baseline mean VF MD is -7.5±6.8 dB and 38% of eyes underwent prior glaucoma surgical intervention. Data is available for 26 eyes that have reached the 1-month postoperative period. Mean preoperative IOP is 18.4±7.1 mmHg on a mean of 2.7±1.6 medications. Day 1 postoperative mean IOP is 16.7±7.3 mmHg and at 1 month postoperative is 16.9±5.3 mmHg. Due to the short-term follow-up, medication remains similar as the surgeon considers glaucoma medication elimination 4-6 weeks post-surgery.

Conclusions:

Early evidence of safety and performance of iStent inject is demonstrated in this cohort of eyes. Longer-term follow-up along with increased sample size will provide useful real-world clinical evidence on this novel technology recently introduced in the US and regions of EU.  Importantly, this surgeon’s practice comprises of a large Hispanic population; data in this sub-population is sparse but important to help inform surgeons on the usage of the device to treat OAG in Hispanics.

Financial Disclosure:

... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... receives consulting fees, retainer, or contract payments from a competing company